The association between low-level viraemia and subsequent viral non-suppression among people living with HIV/AIDS on antiretroviral therapy in Uganda

Author:

Nanyeenya NicholusORCID,Chang Larry William,Kiwanuka Noah,Nasuuna Esther,Nakanjako Damalie,Nakigozi Gertrude,Kibira Simon P. S.ORCID,Nabadda Susan,Kiyaga Charles,Makumbi Fredrick

Abstract

Background Uganda’s efforts to end the HIV epidemic by 2030 are threatened by the increasing number of PLHIV with low-level viraemia (LLV). We conducted a study to determine the prevalence of LLV and the association between LLV and subsequent viral non-suppression from 2016 to 2020 among PLHIV on ART in Uganda. Method This was a retrospective cohort study, using the national viral load (VL) program data from 2016 to 2020. LLV was defined as a VL result of at least 50 copies/ml, but less than 1,000 copies/ml. Multivariable logistic regression was used to determine the factors associated with LLV, and cox proportional hazards regression model was used to determine the association between LLV and viral non-suppression. Results A cohort of 17,783 PLHIV, of which 1,466 PLHIV (8.2%) had LLV and 16,317 (91.8%) had a non-detectable VL was retrospectively followed from 2016 to 2020. There were increasing numbers of PLHIV with LLV from 2.0% in 2016 to 8.6% in 2020; and LLV was associated with male sex, second line ART regimen and being of lower age. 32.5% of the PLHIV with LLV (476 out of 1,466 PLHIV) became non-suppressed, as compared to 7.7% of the PLHIV (1,254 out of 16,317 PLHIV) with a non-detectable viral load who became non-suppressed during the follow-up period. PLHIV with LLV had 4.1 times the hazard rate of developing viral non-suppression, as compared to PLHIV with a non-detectable VL (adjusted hazard ratio was 4.1, 95% CI: 3.7 to 4.7, p < 0.001). Conclusion Our study indicated that PLHIV with LLV increased from 2.0% in 2016 to 8.6% in 2020, and PLHIV with LLV had 4.1 times the hazard rate of developing viral non-suppression, as compared to PLHIV with a non-detectable VL. Hence the need to review the VL testing algorithm and also manage LLV in Uganda.

Funder

NIH Fogarty International Center

NINDS

NIMH

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference37 articles.

1. Antiretroviral Drug Discovery and Development | NIH: National Institute of Allergy and Infectious Diseases [Internet]. [cited 2021 Nov 6]. Available from: https://www.niaid.nih.gov/diseases-conditions/antiretroviral-drug-development

2. Twenty Years Of Antiretroviral Therapy For People Living With HIV: Global Costs, Health Achievements, Economic Benefits.;SS Forsythe;Health Affairs.,2019

3. Global HIV & AIDS statistics—Fact sheet [Internet]. [cited 2021 Jun 21]. Available from: https://www.unaids.org/en/resources/fact-sheet

4. Uganda [Internet]. [cited 2021 Jun 21]. Available from: https://www.unaids.org/en/regionscountries/countries/uganda

5. Uganda Viral Load Dashboard [Internet]. [cited 2021 Jun 22]. Available from: https://vldash.cphluganda.org/

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3